Infectious Laryngotracheitis Vaccine Research Articles

Spray vaccination with a Newcastle disease virus (NDV)-vectored infectious laryngotracheitis (ILT) vaccine protects commercial chickens from ILT in the presence of maternally-derived antibodies

ABSTRACT Infectious laryngotracheitis (ILT) poses a significant threat to the poultry industry, and vaccines play an important role in protection. However, due to the increasing scale of poultry production, there is an urgent need to develop vaccines that are suitable for convenient immunization methods such as spraying. Previous studies have shown that Newcastle disease virus (NDV)-ILT vaccines administered via intranasal and intraocular routes to commercial chickens carrying maternally-derived antibodies (MDAs) are still protective against ILT. In this study, a recombinant NDV (rNDV) was generated to express infectious laryngotracheitis virus (ILTV) glycoprotein B (gB), named rLS-gB, based on a full-length cDNA clone of the LaSota strain. The protective effect of different doses of rLS-gB administered by spray vaccination to commercial chickens at 1 d of age (doa) was evaluated. The chickens were exposed to 160-μm aerosol particles for 10 min for spray vaccination, and no adverse reactions were observed after vaccination. Despite the presence of anti-NDV MDAs and anti-ILTV MDAs in chickens, the ILTV- and NDV-specific antibody titres were significantly greater in the vaccinated groups than in the unvaccinated group. After challenge with a virulent ILTV strain, no clinical signs were observed in the 107 EID50/ml group compared to the other groups. Furthermore, vaccination with 107 EID50/ml rLS-gB significantly reduced the ILTV viral load and ameliorated gross and microscopic lesions in the trachea of chickens. Overall, these results suggested that rLS-gB is a safe and efficient candidate spray vaccine for ILT and is especially suitable for scaled chicken farms.

Acoustic Detection of Vaccine Reactions in Hens for Assessing Anti-Inflammatory Product Efficacy

Acoustic studies on poultry show that chicken vocalizations can be a real-time indicator of the health conditions of the birds and can improve animal welfare and farm management. In this study, hens vaccinated against infectious laryngotracheitis (ILT) were acoustically recorded for 3 days before vaccine administration (pre-reaction period) and also from vaccination onwards, with the first 5 days being identified as the “reaction period” and the 5 following days as “post reaction”. The raw audio was pre-processed to isolate hen calls and the 13 Mel-frequency cepstral coefficients; then, the spectral centroid and the number of vocalizations were extracted to build the acoustic dataset. The experiment was carried out on the same farm but in two different houses. The hens from one house were assigned to the control group, without administration of the anti-inflammatory product, and the other formed the treatment group. Both acoustic data sets were recorded and processed in the same way. The control group was used to acoustically model the animal reaction to the vaccine and we automatically detected the hens’ vaccine reactions and side effects through acoustics. From Scikit-Learn algorithms, Gaussian Naive Bayes was the best performing model, with a balanced accuracy of 80% for modeling the reactions and non-reactions caused by ILT in the control group. Furthermore, the importance of algorithm permutation highlighted that the centroid and MFCC4 were the most important features in acoustically detecting the ILT vaccine reaction. The fitted Gaussian Naive Bayes model allowed us to evaluate the treatment group to determine if the vocalizations after vaccine administration were detected as non-reactions, due to the anti-inflammatory product’s effectiveness. Of the sample, 99% of vocalizations were classified as non-reactions, due to the anti-inflammatory properties of the product, which reduced vaccine reactions and side effects. The non-invasive detection of hens’ responses to vaccination to prevent respiratory problems in hens described in this paper is an innovative method of measuring and detecting avian welfare.

Seroprevalence and Associated Risk Factors of Infectious Laryngotracheitis (ILT) from Poultry Farms in Selected Towns of East Shao Zone

Poultry is one of the largest group of livestock species in the world in which chickens largely dominate the flock composition. Although this sector has a potential in elevating poverty in one country it is seriously challenged with various factors, of which poultry disease is the main. Infectious laryngotracheitis (ILT) is a highly contagious and upper respiratory disease of chickens which is caused by a Gallid herpesvirus 1 (GaHV-1) belonging to the genus Iltovirus, and subfamily Alphaherpesvirinae within Herpesviridae family was one of a deadly poultry disease which impose to a loss of production and productivity gained from the sector. Cross-sectional study was conducted from December 2022 to April 2023 in three selected cities of Oromia region (Bishoftu, Adama and Modjo), Ethiopia. In the current study area, of the total 386 serum samples collected using simple random sampling method 14 (3.63%; 95%CI: 2.15-6.04) were found positive for anti-ILTV antibody detection using Indirect Enzyme Linked Immuno Sorbent Assay. Prevalence of the disease at flock level was found 5/17 (29.41%; 95% CI: 11.52%- 57.14%). Different risk factors (sex, age, sampling area, breed, production type, origin, management and supplementation of vitamins) were considered as covariates for this study. Of the different risk factors considered; sampling area, production type, age, origin and management were found statistically significant (p<0.05) whereas the rest factors were not significantly associated with the outcome variable using chi-square analysis. However, using logistic regression model sampling area and management were found significantly associated (p<0.05) with the occurrence of the disease. The result of this study revealed that ILT virus is circulating among commercial chickens in the selected study areas and needs due emphasis to tackle and cease its spread using vaccination, although ILT vaccine is not familiarized now days in Ethiopia. In addition, proper management and biosecurity measures will be highly recommended as the disease is a deadly disease once introduced into the farm

In Ovo Vaccination with Recombinant Herpes Virus of the Turkey-Laryngotracheitis Vaccine Adjuvanted with CpG-Oligonucleotide Provides Protection against a Viral Challenge in Broiler Chickens.

Infectious laryngotracheitis (ILT) is an economically important disease in chickens. We previously showed that an in ovo adjuvantation of recombinant herpesvirus of the turkey-Laryngotracheitis (rHVT-LT) vaccine with CpG-oligonucleotides (ODN) can boost vaccine-induced responses in one-day-old broiler chickens. Here, we evaluated the protective efficacy of in ovo administered rHVT-LT + CpG-ODN vaccination against a wild-type ILT virus (ILTV) challenge at 28 days of age and assessed splenic immune gene expression as well as cellular responses. A chicken-embryo-origin (CEO)-ILT vaccine administered in water at 14 days of age was also used as a comparative control for the protection assessment. The results showed that the rHVT-LT + CpG-ODN or the CEO vaccinations provided significant protection against the ILTV challenge and that the level of protection induced by both the vaccines was statistically similar. The protected birds had a significantly upregulated expression of interferon (IFN)γ or interleukin (IL)-12 cytokine genes. Furthermore, the chickens vaccinated with the rHVT-LT + CpG-ODN or CEO vaccine had a significantly higher frequency of γδ T cells and activated CD4+ or CD8+ T cells, compared to the unvaccinated-ILTV challenge control. Collectively, our findings suggest that CpG-ODN can be used as an effective adjuvant for rHVT-LT in ovo vaccination to induce protective immunity against ILT in broiler chickens.

Protection Efficacy of the Infectious Laryngotracheitis (ILT) Serva CEO Vaccine Strain in Broiler Chickens Under Different Vaccination Coverage Conditions.

Mass vaccination against infectious laryngotracheitis virus (ILTV) in drinking water can result in variable initial vaccine take. Partial initial vaccine coverage of 20% with an Australian ILT vaccine (A20) previously resulted in significant protection against virulent ILTV challenge. This follow-up study used the international Serva ILT vaccine strain in a factorial design testing four levels of vaccination coverage (0%, 10%, 20%, or 100% of chicks eye-drop vaccinated with the live vaccine at 7 days of age) and three levels of ILTV challenge (no challenge or challenge at 7 or 21 days postvaccination [DPV]). The increase in ILTV load in choanal cleft swabs detected by qPCR after challenge was significantly reduced by 20% and 100% but not by 10% vaccination coverage. Vaccination reduced weight gain in unchallenged birds. Daily weight gain of birds was not affected by ILTV challenge at 7 DPV in any group, but following challenge at 21 DPV, it was significantly reduced in unvaccinated and 10% vaccinated groups relative to 20% and 100% vaccinated groups. Vaccination of 20% of the chickens provided substantial but incomplete protection (protective index range 44%-70%) against the severity of clinical signs and mortality following challenge while 10% vaccination coverage provided limited or no protection. Clinical signs were more severe and appeared earlier following challenge at 21 DPV than at 7 DPV. Within the vaccination treatments, eye-drop-vaccinated birds were better protected than their in-contact cohorts. In conclusion, partial vaccination of 20%, but not 10% of chickens, induced substantial protection against subsequent challenge. However, the attendant risks of reduced protection against early challenge and the possible reversion to virulence of vaccine virus when transmitted to unvaccinated chickens make it essential that 100% initial vaccine take be the goal of mass vaccination programs.

Serological Evidence of Infectious Laryngotracheitis Infection and Associated Risk Factors in Chickens in Northwestern Ethiopia.

Infectious laryngotracheitis (ILT) is a disease of high economic consequence to the poultry sector. Gallid herpesvirus 1 (GaHV-1), a.k.a infectious laryngotracheitis virus (ILTV), under the genus Iltovirus, and the family Herpesviridae, is the agent responsible for the disease. Despite the clinical signs on the field suggestive of ILT, it has long been considered nonexistent and a disease of no concern in Ethiopia. A cross-sectional study was conducted from November 2020 to June 2021 in three selected zones of the Amhara region (Central Gondar, South Gondar, and West Gojjam zones), Ethiopia, with the objective of estimating the seroprevalence of ILTV in chickens and identifying and quantifying associated risk factors. A total of 768 serum samples were collected using multistage cluster sampling and assayed for anti-ILTV antibodies using indirect ELISA. A questionnaire survey was used to identify the potential risk factors. Of the 768 samples, 454 (59.1%, 95% CI: 0.56–0.63) tested positive for anti-ILTV antibodies. Mixed-effect logistic regression analysis of potential risk factors showed that local breeds of chicken were less likely to be seropositive than exotic breeds (OR: 0.38, 95% CI: 0.24–0.61). In addition, factors such as using local feed source (OR: 6.53, 95% CI: 1.77–24.04), rearing chickens extensively (OR: 1.97, 95% CI: 0.78–5.02), mixing of different batches of chicken (OR: 14.51, 95% CI: 3.35–62.77), careless disposal of litter (OR: 1.62, 95% CI: 0.49–4.37), lack of house disinfection (OR: 11.05, 95% CI: 4.09–47.95), lack of farm protective footwear and clothing (OR: 20.85, 95% CI: 5.40–80.45), and careless disposal of dead chicken bodies had all been associated with increased seropositivity to ILTV. Therefore, implementation of biosecurity measures is highly recommended to control and prevent the spread of ILTV. Furthermore, molecular confirmation and characterization of the virus from ILT suggestive cases should be considered to justify the use of ILT vaccines.

Variability in practices for drinking water vaccination of meat chickens against infectious laryngotracheitis

Context Drinking water vaccination of young meat chickens with Infectious Laryngotracheitis (ILT) vaccine is problematic. Vaccine failure and adverse vaccine reactions are frequently reported. Variations in the technique of applying ILT vaccines by this mass vaccination method need to be understood to contribute to improving the success of vaccination. Aims This study aimed to examine variations in the techniques of application of Infectious Laryngotracheitis vaccines via drinking water for young meat chickens. Methods Drinking water vaccination techniques were observed and recorded across 52 broiler flocks during ILT outbreaks in three geographic areas of Australia. Descriptive statistics for all variables were computed and variations between integrator company procedures were statistically compared. Key results Despite rigorous standard operating procedures, wide variations were observed in time of water deprivation prior to vaccination (3–15 min), time drinking water was stabilised prior to addition of vaccine and the type of stabiliser product used, time to activate the flock following filling of the water lines with vaccine (10–127 min), time for the vaccine to be consumed (36–226 min) and the volume of drinking water per bird used to provide the vaccine (11–48 mL/bird). Conclusions Variation in vaccination technique can affect the success of drinking water vaccination against ILT in young meat chickens. Implications Understanding the importance of the variable factors in vaccine application method can improve the success of water vaccination against ILT.

Spiky titanium dioxide nanoparticles-loaded Plantaginis Semen polysaccharide as an adjuvant to enhance immune responses

The purpose of this study was to prepare spiky titanium dioxide nanoparticles-loaded Plantaginis Semen polysaccharide (SN-TiO2-PSP), and the structural characterization and immune response of infectious laryngotracheitis (ILT) vaccine in Hetian chickens were investigated. The structural characterization of SN-TiO2-PSP was analyzed by FT-IR, TEM, and TGA analysis. And the immune organs indexes, lymphocytes proliferation, specific antibody levels, and ratios of CD4+ and CD8+ T lymphocytes were studied. Structural characterization results showed that SN-TiO2-PSP has a typical polysaccharide absorption peak and good stability. The SN-TiO2-PSP's shape was similar to sea urchin, and its zeta potential and particle size were 27.56 mV and 976.11 nm, respectively. In vivo results showed that SN-TiO2-PSP could enhance the proliferation of peripheral lymphocytes, specific antibody levels, CD4+ and CD8+ T lymphocytes ratios, IL-4 and INF-γ levels in Hetian chickens vaccinated with ILT vaccine on D7, D14, D21, and D28. In addition, SN-TiO2-PSP not only enhanced the indexes of immune organs but also promoted the development of immune organs. Therefore, SN-TiO2-PSP has immune adjuvant activity and may become a new potential immune adjuvant.

Control, Elimination, and Monitoring of Infectious Laryngotracheitis in a Multiage Commercial Layer Pullet Farm in Canada.

A multiage commercial layer pullet operation with a history of chicken embryo (CEO) modified live infectious laryngotracheitis (ILT) virus vaccination suffered severe ILT breaks in 2017. The initial sequencing revealed that the circulating virus was of vaccine origin. Changes to the timing and dosage of CEO ILT vaccine failed to control the outbreak. The clinical resolution of the outbreak occurred with the transition to a turkey herpesvirus vector vaccine given in hatchery followed by a tissue culture origin (TCO) vaccine given before the onset of symptoms on the farm. The circulating ILT viruses were monitored periodically using next generation sequencing. This site became free of ILT virus within one year after implementing the new vaccination program.

Control, Suppression, and Monitoring of Infectious Laryngotracheitis in a Multiage Commercial Layer Pullet Farm in Canada.

A multiage commercial layer pullet operation with a history of chicken embryo-origin (CEO) modified live infectious laryngotracheitis (ILT) virus vaccination suffered severe ILT outbreaks in 2017. The initial sequencing revealed that the circulating virus was of vaccine origin. Changes to the timing and dosage of CEO ILT vaccine failed to control the outbreak. The clinical resolution of the outbreak occurred with the transition to a turkey herpesvirus vector vaccine given in-hatchery, followed by a tissue culture-origin vaccine given on the farm. The circulating ILT viruses were monitored periodically by next-generation sequencing. This site became free of ILT virus within 1 yr after implementing the new vaccination program.

Assessment of A20 infectious laryngotracheitis vaccine take in meat chickens using swab and dust samples following mass vaccination in drinking water

Infectious laryngotracheitis, caused by the alphaherpesvirus infectious laryngotracheitis virus (ILTV), is an important disease of chickens. Partial control of this disease in meat chickens is commonly achieved by mass vaccination with live virus in drinking water. There is a need for a practical test to evaluate vaccination outcomes. For the Serva ILTV vaccine, quantitative real-time PCR (qPCR) enumeration of ILTV genome copies (GC) in flock level dust samples collected at 7–8 days post vaccination (dpv) can be used to differentiate flocks with poor and better vaccine take. This study aimed to validate this approach for A20, another widely used ILT vaccine in Australia. In four meat chicken flocks vaccinated with A20 in water using two different water stabilization times (20 or 40 min), swabs from the trachea and choanal cleft and dust samples were collected at 0, 7, 14 and 21 dpv. ILTV GC detection in swabs and dust was highest at 7 dpv and at this time ILTV GC load in dust was strongly and positively associated with vaccine take in individual birds assessed by swab samples. Choanal cleft swabs provided significantly fewer ILTV positive results than paired tracheal swab samples but the level of ILTV GC detected was similar. Water stabilization time had only minor effects on vaccination response in favour of the shorter time. Location of dust collection had no effect on viral load measured in dust samples. Dust samples collected at 0 and 7 dpv can be used to assess the vaccination status of flocks.

Isolation, identification and chemical inactivation of infectious laryngotracheitis virus for use as a vaccine candidate

Infectious laryngotracheitis (ILT) is a poultry respiratory disease associated with considerable mortality in chicken and decreasing egg production. Vaccination along with biosecurity measures are considered as the main strategy for ILT control. This study was aimed to evaluate the potency of an inactive ILT vaccine candidate derived from a local ILTV isolate. The isolated virus was characterized and treated with various chemicals and their concentrations. The virus infectivity was entirely abolished by treatment of 3 mM binary ethylene imine following 16 h incubation. The immune response of inactivated ILTV suspension with adjuvans was evaluated in both SPF chickens (experiment-I) and Hyline pullets (experiment-II). Efficacy of the inactivated and live ILT vaccines combination was compared. The results of experiment-I showed that the inactivated antigen induced specific antibody titers against ILTV. In experiment-II, despite the increase in serum antibody level administration of the inactivated antigen alone did not offer sufficient protection. The full protection was found in chickens that received the combination regimen. We conclude that simultaneous administration of the inactivated and live ILT vaccines was efficient for induction of immunity against ILTV. Keywords: infectious laryngotracheitis virus; vaccine; inactivation; immune response.

Preparation And Evaluation Of A Recent Infectious Laryngotracheitis (Ilt) Vaccine From A Local Field Isolate

Infectious laryngotracheitis (ILT) is a respiratory tract disease affecting chickens worldwide. The disease leads to severe production losses due to increased mortality, decreased egg production, and delayed body weight gain, causing enormous economic losses to the poultry industry. ILT is controlled through vaccination with live-modified attenuated vaccines of chicken embryo origin (CEO) and/or the tissue-culture origin (TCO). This study was conducted to develop Specific Pathogenic Free (SPF) egg-adapted live attenuated ILT vaccine from the field strain Fayoum_2018 isolated from broilers in Fayoum Province, Egypt in 2018. The isolate Fayoum_2018 with accession number (MN082684) was characterized molecularly as a TCO vaccine related strain. Measurement of immunity in vaccinated chicks employing the potency test revealed that chicks vaccinated with 0.5 ml of prepared ILT vaccine exhibited ELISA with 1905 antibody titer at 2nd-week post-vaccination, which was considered an ILT adequate immune response and increased till reach 3497 antibody titer at 6th-week post-vaccination. The current work revealed that Fayoum_2018 ILTV egg adapted live attenuated vaccine produced a satisfactory antibodies titer that was efficient in controlling the ILT field infection in Egypt.

Genomic recombination between infectious laryngotracheitis vaccine strains occurs under a broad range of infection conditions in vitro and in ovo.

Gallid alphaherpesvirus 1 causes infectious laryngotracheitis (ILT) in farmed poultry worldwide. Intertypic recombination between vaccine strains of this virus has generated novel and virulent isolates in field conditions. In this study, in vitro and in ovo systems were co-infected and superinfected under different conditions with two genomically distinct and commonly used ILTV vaccines. The progeny virus populations were examined for the frequency and pattern of recombination events using multi-locus high-resolution melting curve analysis of polymerase chain reaction products. A varied level of recombination (0 to 58.9%) was detected, depending on the infection system (in ovo or in vitro), viral load, the composition of the inoculum mixture, and the timing and order of infection. Full genome analysis of selected recombinants with different in vitro phenotypes identified alterations in coding and non-coding regions. The ability of ILTV vaccines to maintain their capacity to recombine under such varied conditions highlights the significance of recombination in the evolution of this virus and demonstrates the capacity of ILTV vaccines to play a role in the emergence of recombinant viruses.

A practical method for assessing infectious laryngotracheitis vaccine take in broilers following mass administration in water: Spatial and temporal variation in viral genome content of poultry dust after vaccination

Infectious laryngotracheitis is an important disease of chickens caused by infectious laryngotracheitis virus (ILTV). Outbreaks commonly occur in meat chicken flocks and mass vaccination with live attenuated vaccines, usually in water, is used to control the disease in these populations. Vaccination with live virus via water and nipple drinkers requires stringent adherence to protocols to ensure success, but vaccine administration monitoring is not currently assessed due to a lack of economically viable methods. Vaccinal ILTV has been shown to be detectable in dust in experimental studies and has potential as a method of assessing vaccination success. However, the pattern of vaccinal ILTV detection in dust following vaccination under commercial conditions has not been defined. We report the longitudinal profile of ILTV genome copies (GC) in poultry house dust collected on settle plates following vaccination of 8 flocks of commercial meat chickens on four farms. ILTV GC was enumerated using quantitative real-time polymerase chain reaction (qPCR). There was considerable variation between flocks in the levels of ILTV GC detected post vaccination and this variation was significantly associated with vaccine take measured in individual birds in a companion study. There was no effect of sampling location on ILTV GC in dust but the amount of dust collected was greater in locations closer to the exhaust fans in artificially ventilated houses. Results indicate that measurement of ILTV GC in single or pooled dust samples at 7–8 days post vaccination enables detection of poor vaccine takes and provides a practical means of monitoring ILT vaccination.

Evaluation of vaccination against infectious laryngotracheitis (ILT) with recombinant herpesvirus of turkey (rHVT-LT) and chicken embryo origin (CEO) vaccines applied alone or in combination

ABSTRACTThe chicken embryo origin (CEO) infectious laryngotracheitis (ILT) live attenuated vaccines, although capable of protecting against disease and reducing challenge virus replication, can regain virulence. Recombinant ILT vaccines do not regain virulence but are partially successful at blocking challenge virus replication. The objective of this study was to evaluate the effect of rHVT-LT vaccination on CEO replication and how this vaccination strategy enhances protection and limits challenge virus transmission to naïve contact chickens. The rHVT-LT vaccine was administered at 1 day of age subcutaneously and the CEO vaccine was administered at 6 weeks of age via eye-drop or drinking water. CEO vaccine replication post vaccination, challenge virus replication and transmission post challenge were evaluated. After vaccination, only the group that received the CEO via eye-drop developed transient conjunctivitis. A significant decrease in CEO replication was detected for the rHVT-LT + CEO groups as compared to groups that received CEO alone. After challenge, reduction in clinical signs and challenge virus replication were observed in all vaccinated groups. However, among the vaccinated groups, the rHVT-LT group presented higher clinical signs and challenge virus replication. Transmission of the challenge virus to naïve contact chickens was only observed in the rHVT-LT vaccinated group of chickens. Overall, this study found that priming with rHVT-LT reduced CEO virus replication and the addition of a CEO vaccination provided a more robust protection than rHVT alone. Therefore, rHVT-LT + CEO vaccination strategy constitutes an alternative approach to gain better control of the disease.

Uptake and spread of infectious laryngotracheitis vaccine virus within meat chicken flocks following drinking water vaccination

Vaccination against infectious laryngotracheitis virus (ILTV) in commercial broiler flocks in the field, which is only undertaken in the face of a local outbreak, requires mass administration techniques, usually via drinking water. This is often fraught with difficulties such as variable vaccination “reactions” and sometimes, vaccination failure. Laboratory testing of the outbreak strains however invariably shows the vaccines in use to be protective. To investigate this paradox, the dynamics of an ILT vaccine virus was examined within broiler flocks during a natural outbreak. In an initial flock, 70 birds were individually identified and had tracheal swabs collected sequentially at intervals from 1 to 26 days after vaccination and submitted for ILTV detection using qPCR. This evaluation was extended by collection of tracheal swabs from 40 to 45 random birds at 4, 7–8, 12–13 and 25–26 days post vaccination (pv) across a further 7 flocks. The results showed a very variable early uptake of vaccine virus from the drinking water (between 3% and 52% of tested birds with detectable virus in trachea at 4 days pv) and revealed that actual vaccination of the flocks relied on bird to bird transmission of the vaccine virus. In flocks with very low (<10%) initial bird uptake, successful exposure of vaccine virus to the majority of the flock can be delayed, leaving a large proportion of birds as susceptible at the likely time of possible exposure to wild virus. This may explain the cases of apparent failure of vaccination in the field. The variable bird to bird spread can be associated with reversion to virulence, this may explain the rolling vaccine reactions often observed. The variation in initial vaccine uptake may be affected by some factors involved with the administration technique and this requires further study in a larger sample size.

Protection Efficacy of a Recombinant Herpesvirus of Turkey Vaccine Against Infectious Laryngotracheitis Virus Administered In Ovo to Broilers at Three Standardized Doses.

Infectious laryngotracheitis (ILT) is a highly contagious respiratory disease of chickens that produces significant economic losses to the poultry industry. The disease is caused by Gallid alpha herpesvirus-1 (GaHV-1), commonly known as the infectious laryngotracheitis virus (ILTV). Vaccination remains necessary for the control of the disease. Due to the inherent virulence of live attenuated vaccines, in particular that of the chicken embryo origin (CEO) vaccines, the use of ILT viral vector recombinant vaccines has significantly expanded worldwide as a safer vaccination strategy. However, the protective efficacy of recombinant ILT vaccines can be compromised by the use of fractional doses and improper handling and administration of the vaccine. The objective of this study was twofold: 1) to evaluate the protection efficacy induced by a commercial recombinant HVT-LT (rHVT-LT) vaccine when administered in ovo to broilers at three standardized doses (6000 plaque-forming units [PFU], 3000 PFU, and 1000 PFU), and 2) to assess the potential of rHVT-LT-vaccinated chickens to spread virus to contact chickens after challenge. Independently of the vaccine dose, vaccinated chickens showed reduction in clinical signs, maintained body weight gain after challenge, and lessened the challenge virus replication in the trachea at a rate of 52%-65%. However, in spite of this reduction, transmission of challenge virus from rHVT-LT-vaccinated (6000/Ch, 3000/Ch) to contact-naive chickens was evident. This study is the first to support that rHVT-LT vaccination did not prevent spread of challenge virus to contact birds.

Commercial Vaccines and Vaccination Strategies Against Infectious Laryngotracheitis: What We Have Learned and Knowledge Gaps That Remain

Infectious laryngotracheitis (ILT) is an upper respiratory disease of chickens, pheasants, and peafowl caused by the alphaherpesvirus Gallid alpha herpesvirus 1 (GaHV-1), commonly known as infectious laryngotracheitis virus. ILT is an acute respiratory disease characterized by clinical signs of conjunctivitis, nasal discharge, dyspnea, and lethargy. In severe forms of the disease, hemorrhagic tracheitis together with gasping, coughing, and expectoration of bloody mucus are common. The morbidity and mortality rates of the disease vary depending on the virulence of the strain circulating, the level of virus circulating in the field, and the presence of other respiratory infections. Since the identification of the disease in the 1920s, ILT continues to affect the poultry industry negatively across the globe. The disease is primarily controlled by a combination of biosecurity and vaccination. The first commercial vaccines, introduced in the late 1950s and early 1960s, were the chicken embryo origin live attenuated vaccines. The tissue culture origin vaccine was introduced in late 1970s. Recombinant viral vector ILT vaccines were first introduced in the United States in the 2000s, and now they are being used worldwide, alone or in combination with live attenuated vaccines. This review article provides a synopsis of what we have learned about vaccines and vaccination strategies used around the world and addresses knowledge gaps about the virus and host interactions that remain unknown.

Chicken interferon gamma fold expression level and tracheal lesion score differences between commercial broiler chickens vaccinated with live and vectored ILT vaccines

Infectious laryngotracheitis (ILT) is a respiratory tract disease affecting chickens around the world. The disease generates severe production losses due to increased mortality, decreased egg production, delayed body weight gain, and a predisposition to other respiratory pathogens causing enormous economic losses to the intensive poultry industry. Two licensed vaccines, comprising live or vectored ILT, are available to control the disease. The present trial was conducted to determine changes in chicken interferon gamma fold expression levels in chicken spleens and to evaluate tracheal lesion scores before and after vaccination with live and vectored infectious laryngotracheitis vaccines. Broilers were kept under commercial conditions until 35 days of age. Spleen and trachea samples were taken at 14, 28, and 35 days of age. Tracheas were stained with H&amp;E, histopathology was performed, and the INF-γ fold expression level in spleen samples was analyzed. In the spleens of birds vaccinated with the live ILT vaccine, the increase in INF-γ expression levels was statistically significantly (p &lt; 0.01) lower at 28 days of age, or 7 days post vaccination, (trial 1) and higher at 35 days of age, or 14 days post vaccination, (both trials). At 7 days post vaccination with the live ILT vaccine, the mean tracheal lesion score was significantly higher (p &lt; 0.01) than it was in the control group (both trials). At 14 days post vaccination with the live ILT vaccine, the mean tracheal lesion score was significantly higher (p &lt; 0.05) than it was in the control group 3 (trial 1). No significant differences were found between the control group 3 and group 2, which was vaccinated with the vectored HVT/LT vaccine (both trials). The results of the histology of trachea lesions indicate that vaccination with live ILT may have induced early local immunity. The INF-γ analysis results might indicate that the birds in group 2 (HVT/LT) did not develop local immunity until 35 days of age From the practical point of view, the vectored ILT vaccine is more beneficial because of its ease of administration in the hatchery, lower labor cost, and the absence of clinical signs post vaccination. Its potential drawback, however, is poor local immunity and the slow onset of optimal immunity in commercial broiler chickens